Reviews Albumin Human, USP, 25% Solution


No reviews yet.

Buminate 25% Drug Description
BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized
with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours
at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative.
Store at room temperature, not to exceed 30°C (86°F). Avoid freezing
to prevent damage to the bottle. See attached directions for use. Caution:
In patients with marked dehydration additional fluids must accompany or follow
administration of this product. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Single dose container.
Discard partially used bottle.
The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION
BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.
The likelihood of the presence of viable hepatitis viruses has been minimized
by heating the product for 10 hours at 60°C. This procedure has been shown
to be an effective method of inactivating hepatitis virus in albumin solutions
even when those solutions were prepared from plasma known to be infective.1-3
REFERENCES
1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological
studies on the products of human plasma fractionation. XXXVI. Inactivation of
the virus of homologous serum hepatitis in solutions of normal human serum albumin
by means of heat. J Clin Invest 27:239-244, 1948
2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion
22:347-351, 1982
3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of
serum hepatitis from blood and blood products. NY State J Med 55:1145-1150,
1955Last reviewed on RxList: 1/20/2009




Buminate 25% Drug Description
BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized
with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours
at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative.
Store at room temperature, not to exceed 30°C (86°F). Avoid freezing
to prevent damage to the bottle. See attached directions for use. Caution:
In patients with marked dehydration additional fluids must accompany or follow
administration of this product. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Single dose container.
Discard partially used bottle.
The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION
BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.
The likelihood of the presence of viable hepatitis viruses has been minimized
by heating the product for 10 hours at 60°C. This procedure has been shown
to be an effective method of inactivating hepatitis virus in albumin solutions
even when those solutions were prepared from plasma known to be infective.1-3
REFERENCES
1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological
studies on the products of human plasma fractionation. XXXVI. Inactivation of
the virus of homologous serum hepatitis in solutions of normal human serum albumin
by means of heat. J Clin Invest 27:239-244, 1948
2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion
22:347-351, 1982
3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of
serum hepatitis from blood and blood products. NY State J Med 55:1145-1150,
1955Last reviewed on RxList: 1/20/2009




Buminate 25% Drug Description
BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized
with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours
at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative.
Store at room temperature, not to exceed 30°C (86°F). Avoid freezing
to prevent damage to the bottle. See attached directions for use. Caution:
In patients with marked dehydration additional fluids must accompany or follow
administration of this product. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Single dose container.
Discard partially used bottle.
The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION
BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.
The likelihood of the presence of viable hepatitis viruses has been minimized
by heating the product for 10 hours at 60°C. This procedure has been shown
to be an effective method of inactivating hepatitis virus in albumin solutions
even when those solutions were prepared from plasma known to be infective.1-3
REFERENCES
1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological
studies on the products of human plasma fractionation. XXXVI. Inactivation of
the virus of homologous serum hepatitis in solutions of normal human serum albumin
by means of heat. J Clin Invest 27:239-244, 1948
2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion
22:347-351, 1982
3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of
serum hepatitis from blood and blood products. NY State J Med 55:1145-1150,
1955Last reviewed on RxList: 1/20/2009




Buminate 25% Drug Description
BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized
with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours
at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative.
Store at room temperature, not to exceed 30°C (86°F). Avoid freezing
to prevent damage to the bottle. See attached directions for use. Caution:
In patients with marked dehydration additional fluids must accompany or follow
administration of this product. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Single dose container.
Discard partially used bottle.
The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION
BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.
The likelihood of the presence of viable hepatitis viruses has been minimized
by heating the product for 10 hours at 60°C. This procedure has been shown
to be an effective method of inactivating hepatitis virus in albumin solutions
even when those solutions were prepared from plasma known to be infective.1-3
REFERENCES
1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological
studies on the products of human plasma fractionation. XXXVI. Inactivation of
the virus of homologous serum hepatitis in solutions of normal human serum albumin
by means of heat. J Clin Invest 27:239-244, 1948
2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion
22:347-351, 1982
3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of
serum hepatitis from blood and blood products. NY State J Med 55:1145-1150,
1955Last reviewed on RxList: 1/20/2009




Buminate 25% Drug Description
BUMINATE 25%
Albumin (Human), USP, 25% Solution

This bottle contains 25 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 500 mL of normal human plasma. It has been stabilized
with sodium caprylate and sodium acetyltryptophanate and heated for 10 hours
at 60°C. The sodium content is 145 ± 15 mEq/L. Contains no preservative.
Store at room temperature, not to exceed 30°C (86°F). Avoid freezing
to prevent damage to the bottle. See attached directions for use. Caution:
In patients with marked dehydration additional fluids must accompany or follow
administration of this product. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Single dose container.
Discard partially used bottle.
The patient and physician should discuss the risks and benefits of this product.

DRUG DESCRIPTION
BUMINATE 25%, Albumin (Human), 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin and is prepared from human venous plasma using the Cohn cold ethanol fractionation process. Source material for fractionation may be obtained from another U.S. licensed manufacturer. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with sodium acetyltryptophanate and sodium caprylate. The sodium content is 145 ± 15 mEq/L. This solution contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. BUMINATE 25%, Albumin (Human), 25% Solution is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color.
The likelihood of the presence of viable hepatitis viruses has been minimized
by heating the product for 10 hours at 60°C. This procedure has been shown
to be an effective method of inactivating hepatitis virus in albumin solutions
even when those solutions were prepared from plasma known to be infective.1-3
REFERENCES
1. Gellis SS, Neefe JR, Stokes J Jr, et al: Chemical, clinical and immunological
studies on the products of human plasma fractionation. XXXVI. Inactivation of
the virus of homologous serum hepatitis in solutions of normal human serum albumin
by means of heat. J Clin Invest 27:239-244, 1948
2. Gerety RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion
22:347-351, 1982
3. Murray R, Diefenbach WCL, Geller H, et al: Problem of reducing danger of
serum hepatitis from blood and blood products. NY State J Med 55:1145-1150,
1955Last reviewed on RxList: 1/20/2009





Other reviews about Albumin Human, USP, 25% Solution on wordpress

4/05/09
  by corditecountry
Cordite Country Show Notes for Sunday-April 5, 2009 Topics: Diabetes; Camping Precautions/Tips; Snakes; Bears; Walnut; Huckleberry; Blackberry; Chestnut. Diabetes Each day in the United States, some 18 million people with […]


Live Saving Drugs and Medical Care in the Global Manusmriti Zionist Village Post Modern
  by palashbiswaskl
Live Saving Drugs and Medical Care in the Global Manusmriti Zionist Village Post Modern ツ Trouble Galaxy Destroyed Dreams: chapter 258 ツ Palash Biswas ツ ツ Health care in India […]


GlaxoSmithKline - Vaccines (2009)
  by El Horror
About - ACWY Vax: Meningococcal polysaccharides serogroups A, C, W135 and Y. - Ambirix: Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed). - Arepanrix: AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine. - […]


One more step towards the cure of cancer! Dr. Jose Emilio Fehr Pereira Lopes
  by vanessahughesglion
Sorry, no pictures were allowed! I left the discription of it, just for the knowledge! 1.0 Introduction 1.1 History of the defense system of plants and their medicinal use The defense system […]


What makes you think she ev
  by lschlbshth
I bumped my bad arm putting up another crate to stand on! Riots broke out in London, York, and elsewhere, and hundreds of Israelites were brutally massacred. 119:62 […]


So Dorothy sat on the hearthshelf of
  by ikdrqkscrfcy
Mysteries hedged him on all sides, warnings ran before his heavy feet, and countersigns were muttered behind his attentive back. Ill think of it, but mind you, Mac, […]


Perhaps it was the ba
  by jnwdgdsqfv
1:10 I was in the Spirit on the Lords day, and heard behind me a great voice, as of a trumpet, 1:11 Saying, I am Alpha and Omega, […]


Let it be, and hasten
  by himgyjdtintjgi
Marmeladov paying no attention to the new arrivals continued his story. While these things were happening we had been at war with Mexico for two years 18461848, because […]


What my sensations were no language ca
  by hilmyazrqygec
Sure whatever else we met we should meet our foe. Then he looked down confusedly. This was followed by a long period of silence. Theyre […]


And to save his face he turned fierc
  by bnsvofwgpqi
Only he would not risk his secret that far. What had seemed so easy and simple up at the Glen seemed very different down here. By all the […]



Other reviews about Albumin Human, USP, 25% Solution on web:

FLEXBUMIN 25% [Albumin (Human)] FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous ... AlbuminTherapy.com | Albumin Therapy Products | FLEXBUMIN


Learn about the prescription medication Buminate 25% (Albumin Human, USP, 25% Solution), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Buminate 25% (Albumin Human, USP, 25% Solution) Drug Information ...


FLEXBUMIN 25% [Albumin (Human)] FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous ... AlbuminTherapy.com | Information About Albumin Therapy


ZLB Behring LLC Albumin (Human) USP, 25% US ... Albumin (Human) USP, 25% Albuminar テつョ-25 R x only DESCRIPTION Albumin (Human) 25%, Albuminar テつョ-25 is a sterile aqueous solution of albumin obtained ... ZLB Behring


BUMINATE 25%, Albumin (Human), USP, 25% Solution DESCRIPTION BUMINATE 25%, in 20, 50 and 100 mL glass bottles is a sterile, nonpyrogenic preparation of albumin in a single dosage form ... BUMINATE 25%, Albumin (Human), USP, 25% Solution


FLEXBUMIN 25%, Albumin (Human), USP, 25% Solution, 100 mL Baxter US Product Catalog - FLEXBUMIN 25%, Albumin (Human), USP ...


Albumarc テつョ Albumin (Human), USP, 25% Solution Albumarc テつョ 25% DESCRIPTION This product is derived from blood collected from volunteer donors. Albumin (Human), 25% Solution, Albumarc テつョ 25% ... Albumarcテつョ Albumin (Human), USP, 25% Solution Albumarcテつョ25%


FLEXBUMIN 25% [Albumin (Human)] Indication. FLEXBUMIN 25%, Albumin (Human), USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for ... August 18, 2006


08938273 (Rev. January 2005) Albumin (Human) 25%, USP Plasbumin w-25 DESCRIPTION Albumin ... Plasbumin-25 is a 25% sterile solution of albumin in an aqueous diluent. Albumin (Human) 25%, USP Plasbumin w-25


What form(s) does Plasbumin and Albumin (Human) Solution USP come in? Plasbumin テつョ-25 & Albumin (Human) 25% Solution USP. Each vial of sterile, aqueous solution for i.v. administration ... Plasbumin and Albumin (Human) Solution USP - Uses, Side Effects ...





Featured Reviews

Reviews Revia

Revia Drug Description DRUG DESCRIPTION What are the possible side effects of naltrexone oral (ReVia)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of...
Read More  |  Review This
Reviews Depo-Estradiol

Depo-Estradiol Drug Description DEPO®-ESTRADIOL (estradiol cypionate) Injection, USP WARNINGS: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate...
Read More  |  Review This
Reviews Budesonide Inhalation Powder

Pulmicort Flexhaler Drug Description PULMICORT FLEXHALER™ (Budesonide Inhalation Powder) 90 MCG, 180 MCG DRUG DESCRIPTION What are the possible side effects of budesonide inhalation (Pulmicort Flexhaler, Pulmicort Respules)? Get...
Read More  |  Review This
Reviews Entocort EC

Entocort EC Drug Description Entocort® EC (budesonide) Capsules DRUG DESCRIPTION What are the possible side effects of budesonide (Entocort EC)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Flo-Pred

Flo-Pred Drug Description Flo-Pred (prednisolone acetate) Suspension for Oral use DRUG DESCRIPTION What are the possible side effects of prednisolone? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....